Department of Public Health (E.J.A.W., E.V., H.F.L.), Erasmus MC University Medical Center, Rotterdam, the Netherlands.
Department of Radiology and Nuclear Medicine (K.C.J.C., A.v.d.L.), Erasmus MC University Medical Center, Rotterdam, the Netherlands.
Stroke. 2020 Jul;51(7):1941-1950. doi: 10.1161/STROKEAHA.119.026731. Epub 2020 Jun 17.
Before 2015, endovascular treatment (EVT) for acute ischemic stroke was considered a promising treatment option. Based on limited evidence, it was performed in several dedicated stroke centers worldwide on selected patients. Since 2015, EVT for patients with intracranial large vessel occlusion has quickly been implemented as standard treatment in many countries worldwide, supported by the revised international guidelines based on solid evidence from multiple clinical trials. We describe the development in use of EVT in the Netherlands before, during, and after the pivotal EVT trials. We used data from all patients who were treated with EVT in the Netherlands from January 2002 until December 2018. We undertook a time-series analysis to examine trends in the use of EVT using Poisson regression analysis. Incidence rate ratios per year with 95% CIs were obtained to demonstrate the impact and implementation after the publication of the EVT trial results. We made regional observation plots, adjusted for stroke incidence, to assess the availability and use of the treatment in the country. In the buildup to the MR CLEAN (Multicenter Clinical Trial of Endovascular Treatment of Acute Ischemic Stroke in the Netherlands), a slow increase of EVT patients was observed, with 0.2% of all ischemic stroke patients receiving EVT. Before the trial results were formally announced, a statistically significant increase in EVT-treated patients per year was observed (incidence rate ratio, 1.72 [95% CI, 1.46-2.04]), and after the trial publication, an immediate steep increase was seen, followed by a more gradual increase (incidence rate ratio, 2.14 [95% CI, 1.77-2.59]). In 2018, the percentage of ischemic stroke patients receiving EVT increased to 5.8%. A well-developed infrastructure, a pragmatic approach toward the use of EVT in clinical practice, in combination with a strict adherence by the regulatory authorities to national evidence-based guidelines has led to successful implementation of EVT in the Netherlands. Ongoing efforts are directed at further increasing the proportion of stroke patients with EVT in all regions of the country.
在 2015 年之前,血管内治疗(EVT)被认为是急性缺血性脑卒中的一种有前途的治疗选择。基于有限的证据,它在世界范围内的几个专门的脑卒中中心对选定的患者进行了治疗。自 2015 年以来,基于多个临床试验的可靠证据,修订后的国际指南支持将 EVT 用于颅内大血管闭塞患者,这一治疗方法在世界许多国家迅速成为标准治疗方法。我们描述了在关键的 EVT 试验之前、期间和之后,荷兰 EVT 使用的发展情况。我们使用了 2002 年 1 月至 2018 年 12 月期间在荷兰接受 EVT 治疗的所有患者的数据。我们采用泊松回归分析进行时间序列分析,以检查 EVT 使用的趋势。我们获得了每年的发病率比及其 95%置信区间,以展示在 EVT 试验结果公布后的影响和实施情况。我们绘制了区域观察图,对治疗的可用性和使用情况进行了调整,以评估该国家的情况。在 MR CLEAN(荷兰多中心临床试验中血管内治疗急性缺血性脑卒中)之前,EVT 患者的数量呈缓慢增长趋势,仅有 0.2%的缺血性脑卒中患者接受了 EVT。在正式宣布试验结果之前,我们观察到每年接受 EVT 治疗的患者数量呈统计学显著增加(发病率比为 1.72[95%CI,1.46-2.04]),在试验发表后,立即出现急剧增加,随后增加速度放缓(发病率比为 2.14[95%CI,1.77-2.59])。2018 年,接受 EVT 的缺血性脑卒中患者比例增加到 5.8%。完善的基础设施、在临床实践中对 EVT 的务实应用方法,以及监管机构对国家循证指南的严格遵守,共同推动了 EVT 在荷兰的成功实施。目前正在努力进一步提高该国所有地区接受 EVT 的脑卒中患者的比例。